| Dr Andrew Paul Abbeg, DO | |
|
200 Health Care Dr, Greenville, IL 62246-1154 | |
| (618) 664-1230 | |
| Not Available |
| Full Name | Dr Andrew Paul Abbeg |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 15 Years |
| Location | 200 Health Care Dr, Greenville, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548490311 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 036.129778 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital | Belleville, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Services Midwest Sc | 2769746056 | 20 |
News Archive
TrialReach, the world's largest provider of clinical trial information, today announced it has raised a $13.5M Series B financing round led by Smedvig Capital with participation from existing investors Amadeus Capital Partners and Octopus Investments. With one of the biggest digital health rounds ever raised in the United Kingdom, TrialReach plans to use the funds to support the growth of its clinical trial platform and expansion into the U.S..
Viruses have a bad rep—and rightly so. The ability of a virus to quickly and precisely replicate itself makes it a destructive scourge to animals and plants alike. Now an interdisciplinary team of researchers at the University of Maryland's A. James Clark School of Engineering and College of Agriculture and Natural Resources, brought together by Professor Reza Ghodssi, is turning the tables, harnessing and exploiting the "self-renewing" and "self-assembling" properties of viruses for a higher purpose: to build a new generation of small, powerful and highly efficient batteries and fuel cells.
Previous studies have shown that chrysophanol protects against learning and memory impairments in lead-exposed adult mice.
The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group's results for the first half 2009, published today. The full 2009 half year financial report is available on the Group's web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.
The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.
› Verified 6 days ago
| Entity Name | Cepamerica Illinois Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912283110 PECOS PAC ID: 3274793633 Enrollment ID: O20120322000587 |
News Archive
TrialReach, the world's largest provider of clinical trial information, today announced it has raised a $13.5M Series B financing round led by Smedvig Capital with participation from existing investors Amadeus Capital Partners and Octopus Investments. With one of the biggest digital health rounds ever raised in the United Kingdom, TrialReach plans to use the funds to support the growth of its clinical trial platform and expansion into the U.S..
Viruses have a bad rep—and rightly so. The ability of a virus to quickly and precisely replicate itself makes it a destructive scourge to animals and plants alike. Now an interdisciplinary team of researchers at the University of Maryland's A. James Clark School of Engineering and College of Agriculture and Natural Resources, brought together by Professor Reza Ghodssi, is turning the tables, harnessing and exploiting the "self-renewing" and "self-assembling" properties of viruses for a higher purpose: to build a new generation of small, powerful and highly efficient batteries and fuel cells.
Previous studies have shown that chrysophanol protects against learning and memory impairments in lead-exposed adult mice.
The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group's results for the first half 2009, published today. The full 2009 half year financial report is available on the Group's web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.
The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.
› Verified 6 days ago
| Entity Name | Emergency Services Midwest Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174024806 PECOS PAC ID: 2769746056 Enrollment ID: O20180515000619 |
News Archive
TrialReach, the world's largest provider of clinical trial information, today announced it has raised a $13.5M Series B financing round led by Smedvig Capital with participation from existing investors Amadeus Capital Partners and Octopus Investments. With one of the biggest digital health rounds ever raised in the United Kingdom, TrialReach plans to use the funds to support the growth of its clinical trial platform and expansion into the U.S..
Viruses have a bad rep—and rightly so. The ability of a virus to quickly and precisely replicate itself makes it a destructive scourge to animals and plants alike. Now an interdisciplinary team of researchers at the University of Maryland's A. James Clark School of Engineering and College of Agriculture and Natural Resources, brought together by Professor Reza Ghodssi, is turning the tables, harnessing and exploiting the "self-renewing" and "self-assembling" properties of viruses for a higher purpose: to build a new generation of small, powerful and highly efficient batteries and fuel cells.
Previous studies have shown that chrysophanol protects against learning and memory impairments in lead-exposed adult mice.
The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group's results for the first half 2009, published today. The full 2009 half year financial report is available on the Group's web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.
The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.
› Verified 6 days ago
| Entity Name | Vituity - Illinois Auc Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306334198 PECOS PAC ID: 0547516932 Enrollment ID: O20180627000637 |
News Archive
TrialReach, the world's largest provider of clinical trial information, today announced it has raised a $13.5M Series B financing round led by Smedvig Capital with participation from existing investors Amadeus Capital Partners and Octopus Investments. With one of the biggest digital health rounds ever raised in the United Kingdom, TrialReach plans to use the funds to support the growth of its clinical trial platform and expansion into the U.S..
Viruses have a bad rep—and rightly so. The ability of a virus to quickly and precisely replicate itself makes it a destructive scourge to animals and plants alike. Now an interdisciplinary team of researchers at the University of Maryland's A. James Clark School of Engineering and College of Agriculture and Natural Resources, brought together by Professor Reza Ghodssi, is turning the tables, harnessing and exploiting the "self-renewing" and "self-assembling" properties of viruses for a higher purpose: to build a new generation of small, powerful and highly efficient batteries and fuel cells.
Previous studies have shown that chrysophanol protects against learning and memory impairments in lead-exposed adult mice.
The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group's results for the first half 2009, published today. The full 2009 half year financial report is available on the Group's web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.
The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Paul Abbeg, DO 2100 Powell St, Ste 900, Emeryville, CA 94608-1844 Ph: (510) 851-7423 | Dr Andrew Paul Abbeg, DO 200 Health Care Dr, Greenville, IL 62246-1154 Ph: (618) 664-1230 |
News Archive
TrialReach, the world's largest provider of clinical trial information, today announced it has raised a $13.5M Series B financing round led by Smedvig Capital with participation from existing investors Amadeus Capital Partners and Octopus Investments. With one of the biggest digital health rounds ever raised in the United Kingdom, TrialReach plans to use the funds to support the growth of its clinical trial platform and expansion into the U.S..
Viruses have a bad rep—and rightly so. The ability of a virus to quickly and precisely replicate itself makes it a destructive scourge to animals and plants alike. Now an interdisciplinary team of researchers at the University of Maryland's A. James Clark School of Engineering and College of Agriculture and Natural Resources, brought together by Professor Reza Ghodssi, is turning the tables, harnessing and exploiting the "self-renewing" and "self-assembling" properties of viruses for a higher purpose: to build a new generation of small, powerful and highly efficient batteries and fuel cells.
Previous studies have shown that chrysophanol protects against learning and memory impairments in lead-exposed adult mice.
The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group's results for the first half 2009, published today. The full 2009 half year financial report is available on the Group's web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.
The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.
› Verified 6 days ago
Dr. Delwin Merchant, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Health Care Dr, Greenville, IL 62246 Phone: 618-664-1230 | |
Dr. Adam Earl Stenger, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Health Care Dr, Greenville, IL 62246 Phone: 618-664-1230 | |
Beth Heppermann, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Health Care Dr, Greenville, IL 62246 Phone: 618-664-1230 | |
Dr. Sachin R Patel, M.D., M.P.H. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Health Care Dr, Greenville, IL 62246 Phone: 618-664-1230 | |
Dr. Nicholas D Rathert, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Health Care Dr, Greenville, IL 62246 Phone: 618-664-1230 | |
Ameet S Brahmavar, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Health Care Dr, Greenville, IL 62246 Phone: 618-664-1230 | |
Dr. Daniel Allen Normansell, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Health Care Dr, Greenville, IL 62246 Phone: 618-664-1230 |